Who is sponsoring NCT07478172?

NCT07478172 is sponsored by University of Missouri-Columbia.

What drugs are being tested in NCT07478172?

Interventions in NCT07478172: Whole-body Electrical Muscle Stimulation Exercise.

What condition does NCT07478172 study?

NCT07478172 studies Neuromuscular Diseases (NMD), Amyotrophic Lateral Sclerosis, Myasthenia Gravis, Lambert-eaton Myasthenic Syndrome, Primary Lateral Sclerosis, Spinal Muscular Atrophy, Charcot Marie Tooth Disease (CMT), Fascioscapulohumeral Muscular Dystrophy, Inclusion Body Myositis, Mitochondrial Myopathy, Nemaline Myopathy, Centronuclear Myopathy, Postpolio Syndrome, Pompe Disease (Late-onset), Chronic Inflammatory Demyelinating Polyneuropathy, Hereditary Spastic Paraplegia, Postural Orthostatic Tachycardia Syndrome (POTS), Progressive Muscular Atrophy.

Is NCT07478172 still recruiting?

NCT07478172 is currently recruiting now. Last updated 17 March 2026.

Last reviewed 2026-03-17 · How we verify

NCT07478172

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease

Recruiting now NA Last updated 17 March 2026

What this trial tests

NA trial testing Whole-body Electrical Muscle Stimulation Exercise in Neuromuscular Diseases (NMD) in 50 participants. Currently enrolling.

Timeline

10 March 2026

Primary endpoint
31 December 2030

7 January 2031

Quick facts

Lead sponsor	University of Missouri-Columbia
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	50
Start date	10 March 2026
Primary completion	31 December 2030
Estimated completion	7 January 2031
Sites	1 location across United States

Drugs / interventions tested

Whole-body Electrical Muscle Stimulation Exercise

Conditions studied

Neuromuscular Diseases (NMD) — all drugs for Neuromuscular Diseases (NMD) →
Amyotrophic Lateral Sclerosis — all drugs for Amyotrophic Lateral Sclerosis →
Myasthenia Gravis — all drugs for Myasthenia Gravis →
Lambert-eaton Myasthenic Syndrome — all drugs for Lambert-eaton Myasthenic Syndrome →

Sponsor

University of Missouri-Columbia

Who can join

18 and older, any sex, with Neuromuscular Diseases (NMD) or Amyotrophic Lateral Sclerosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This single-arm pilot study evaluates the effects of whole-body electrical muscle stimulation (WB-EMS) exercise on neuromuscular and physical function in adults with neuromuscular disease (NMD). Due to motor unit impairments, NMD patients often cannot tolerate traditional exercise. WB-EMS bypasses voluntary activation limits by directly stimulating muscle contractions. Up to 50 adults with conditions like ALS, SMA, and MG will undergo 20-minute supervised WB-EMS sessions (1-2 times weekly for 4-8 weeks) using the Katalyst system. Outcomes include neural excitability (TMS), motor unit behavior (EMG, NCS), functional tests (walk, balance, strength), and patient-reported fatigue, pain, and quality of life. Strict safety monitoring and exclusion criteria are in place. This study will provide preliminary data on WB-EMS as a potential exercise modality for NMD.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Neuromuscular Diseases (NMD)

Currently open trials in the same condition.

NCT07021638 — EMMVIES : Walking Training at Home in VIrtual Reality for Children With Chronic Illnesses Impacting Physical Health · NA · recruiting
NCT06573866 — Enhancement of Quality of Work And Life · NA · recruiting
NCT06363357 — The Effect of a Muscle-mimicking, Fabric-type Shoulder Orthosis on Functional Movements of the Upper Limb in Patients Wi · NA · recruiting

Other University of Missouri-Columbia trials

Trials by the same sponsor.

NCT07067502 — Impact of Biphasic Cuirass Ventilation Compared to Non Invasive Ventilation in High Risk Extubations · NA · not yet recruiting
NCT07385105 — Evaluation of Cognitive Behavioral Therapy for Insomnia (CBT-I) in Individuals With Mild Traumatic Brain Injury (mTBI) · NA · not yet recruiting
NCT07424079 — Metacognitive Strategy Training Intervention for Transition-Age Youth With Cerebral Palsy · NA · not yet recruiting
NCT07216196 — The Feasibility of a Remote Problem-Solving Intervention for Autistic Adolescents or Young Adults and a Caregiver · NA · not yet recruiting
NCT07333586 — Insomnia and Insulin Resistance · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07478172 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Missouri-Columbia
Last refreshed: 17 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07478172.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing